IMUGENE LIMITED ORDINARY (IMU) Short Interest
IMUGENE LIMITED ORDINARY (ASX:IMU) had 1.33% of shares reported as short positions as of 26 June 2026, representing 5,521,897 shares. IMUGENE LIMITED ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
IMU
Imugene
Imugene is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. Their pipeline includes B-cell immunotherapies and oncolytic virotherapy technologies designed to activate the immune system against cancer cells. Imugene aims to improve the lives of cancer patients by creating more effective and tolerable treatments.